Literature DB >> 10396237

Ki-67 labelling index and invasiveness among anterior pituitary adenomas: analysis of 103 cases using the MIB-1 monoclonal antibody.

L Mastronardi1, A Guiducci, C Spera, F Puzzilli, F Liberati, G Maira.   

Abstract

AIMS: To investigate the relation between proliferative activity of anterior pituitary adenomas, quantified by the Ki-67 labelling index, and their invasive behaviour.
METHODS: Expression of Ki-67 was evaluated in 103 anterior pituitary adenomas consecutively operated on in a 36 month period and correlated with surgical evidence of invasiveness.
RESULTS: Non-invasive (n = 65) and invasive (n = 38) adenomas were identified from surgically verified infiltration of sellar floor dura and bone. The wall of the cavernous sinus was infiltrated in 16 cases. Forty one adenomas were non-functioning and 62 functioning (24 prolactin, 21 growth hormone, 10 ACTH, seven mixed). The overall mean (SD) Ki-67 labelling index was 2.64 (3.69) per cent (median 1.5). The mean index was 3.08 (4.59) per cent in functioning and 1.97 (1.78) per cent in non-functioning tumours; 5.47 (9.52) per cent in ACTH adenomas and 2.33 (2.42) per cent in others (p = 0.01); 3.71 (5.17) per cent in invasive and 2.01 (2.45) per cent in non-invasive adenomas (p = 0.027); and 5.58 (7.24) per cent in cavernous sinus infiltrating v 2.10 (2.39) per cent in cavernous sinus non-infiltrating adenomas (p = 0.0005). To identify a value of labelling index beyond which adenomas should be considered invasive and another beyond which cavernous sinus infiltration should be suspected, normality Q-Q plots were obtained: a threshold labelling index of 3.5% for invasive adenomas and of 5% for cavernous sinus infiltrating adenomas was defined, with statistically significant differences (p = 0.02 and p = 0.004, respectively).
CONCLUSIONS: The Ki-67 labelling index can be considered a useful marker in determining the invasive behaviour of anterior pituitary adenomas.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10396237      PMCID: PMC501053          DOI: 10.1136/jcp.52.2.107

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  24 in total

1.  INVASIVE PITUITARY ADENOMAS.

Authors:  A N MARTINS; G J HAYES; L G KEMPE
Journal:  J Neurosurg       Date:  1965-03       Impact factor: 5.115

Review 2.  Immunohistochemical markers of cellular proliferation: achievements, problems and prospects.

Authors:  P A Hall; A L Woods
Journal:  Cell Tissue Kinet       Date:  1990-11

Review 3.  Monoclonal antibody Ki-67: its use in histopathology.

Authors:  D C Brown; K C Gatter
Journal:  Histopathology       Date:  1990-12       Impact factor: 5.087

4.  A comparison of proliferation indices in human anterior pituitary adenomas using formalin-fixed tissue and in vitro cell culture.

Authors:  S L Atkin; V L Green; L J Hipkin; A M Landolt; P M Foy; R V Jeffreys; M C White
Journal:  J Neurosurg       Date:  1997-07       Impact factor: 5.115

5.  The correlation of Ki-67 staining indices with tumour doubling times in regrowing non-functioning pituitary adenomas.

Authors:  S M Ekramullah; Y Saitoh; N Arita; T Ohnishi; T Hayakawa
Journal:  Acta Neurochir (Wien)       Date:  1996       Impact factor: 2.216

6.  Dural invasion and proliferative potential of pituitary adenomas.

Authors:  G Daita; Y Yonemasu
Journal:  Neurol Med Chir (Tokyo)       Date:  1996-04       Impact factor: 1.742

7.  Proliferation activity in pituitary adenomas: measurement by monoclonal antibody Ki-67.

Authors:  E Knosp; K Kitz; A Perneczky
Journal:  Neurosurgery       Date:  1989-12       Impact factor: 4.654

8.  Growth rate of human pituitary adenomas.

Authors:  A M Landolt; T Shibata; P Kleihues
Journal:  J Neurosurg       Date:  1987-12       Impact factor: 5.115

9.  Image analysis of proliferating cells in tumors of the human nervous system: an immunohistological study with the monoclonal antibody Ki-67.

Authors:  N J Hopf; J Bremm; J Bohl; A Perneczky
Journal:  Neurosurgery       Date:  1994-11       Impact factor: 4.654

10.  Identification of proliferating cells in human gliomas using the monoclonal antibody Ki-67.

Authors:  P Zuber; M F Hamou; N de Tribolet
Journal:  Neurosurgery       Date:  1988-02       Impact factor: 4.654

View more
  17 in total

Review 1.  Optimal management of non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

2.  Atypical pituitary adenomas: clinical characteristics and role of Ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients.

Authors:  Luciano Mastronardi
Journal:  Neurosurg Rev       Date:  2017-01-22       Impact factor: 3.042

Review 3.  Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review.

Authors:  Sabrina Chiloiro; Antonio Bianchi; Francesco Doglietto; Chiara de Waure; Antonella Giampietro; Alessandra Fusco; Donato Iacovazzo; Linda Tartaglione; Francesco Di Nardo; Francesco Signorelli; Libero Lauriola; Carmelo Anile; Guido Rindi; Giulio Maira; Alfredo Pontecorvi; Laura De Marinis
Journal:  Pituitary       Date:  2014-06       Impact factor: 4.107

4.  Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression.

Authors:  Anniina Raitila; Heli J Lehtonen; Johanna Arola; Elina Heliövaara; Manuel Ahlsten; Marianthi Georgitsi; Anu Jalanko; Anders Paetau; Lauri A Aaltonen; Auli Karhu
Journal:  Am J Pathol       Date:  2010-08-13       Impact factor: 4.307

5.  Predictive modeling for pituitary adenomas: single center experience in 501 consecutive patients.

Authors:  A L Pappy; A Savinkina; C Bicknese; S Neill; N M Oyesiku; A G Ioachimescu
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

6.  High Ki-67 expression is associated with prolactin secreting pituitary adenomas.

Authors:  Bogdan Bălinişteanu; Anca Maria Cîmpean; Amalia Raluca Ceauşu; Ana Silvia Corlan; Eugen Melnic; Marius Raica
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

7.  Nuclear accumulation of basic fibroblast growth factor as a predictor for the recurrence of pituitary adenomas.

Authors:  Shinji Fukui; Naoki Otani; Hiroshi Nawashiro; Akiko Yano; Takahito Miyazawa; Akira Ohnuki; Nobusuke Tsuzuki; Hiroshi Katoh; Shoichiro Ishihara; Takamoto Suzuki; Katsuji Shima
Journal:  J Neurooncol       Date:  2002-05       Impact factor: 4.130

8.  Clinical significance of Ki-67 labeling index in pituitary macroadenoma.

Authors:  Kyung-Il Paek; Seon-Hwan Kim; Shi-Hun Song; Seung-Won Choi; Hyeon-Song Koh; Jin-Young Youm; Youn Kim
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

9.  ACTH and alpha-subunit are co-expressed in rare human pituitary corticotroph cell adenomas proposed to originate from ACTH-committed early pituitary progenitor cells.

Authors:  Masanori Suzuki; Noboru Egashira; Hanako Kajiya; Takeo Minematsu; Susumu Takekoshi; Shigeyuki Tahara; Naoko Sanno; Akira Teramoto; Robert Yoshiyuki Osamura
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

10.  Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Authors:  Maliheh Ghadir; Mohammad E Khamseh; Mahshid Panahi-Shamsabad; Mohammad Ghorbani; Hamideh Akbari; Ali Zare Mehrjardi; Maryam Honardoost; Bahram Jafar-Mohammadi
Journal:  Endocrine       Date:  2020-07-12       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.